Aerovate Therapeutics (NASDAQ:AVTE) Trading Up 14% – What’s Next?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) rose 14% during trading on Thursday . The company traded as high as $16.44 and last traded at $16.02. Approximately 2,237,581 shares were traded during trading, an increase of 17,891% from the average daily volume of 12,438 shares. The stock had previously closed at $14.05.

Aerovate Therapeutics Price Performance

The firm has a market cap of $464.34 million, a price-to-earnings ratio of -5.36 and a beta of 0.95. The business’s 50-day moving average price is $14.61 and its two-hundred day moving average price is $12.66.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in Aerovate Therapeutics by 12.2% during the first quarter. Goldman Sachs Group Inc. now owns 352,669 shares of the company’s stock worth $885,000 after acquiring an additional 38,300 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Aerovate Therapeutics in the 1st quarter valued at about $28,000. Rhumbline Advisers grew its holdings in shares of Aerovate Therapeutics by 67.3% during the 1st quarter. Rhumbline Advisers now owns 22,750 shares of the company’s stock worth $57,000 after purchasing an additional 9,154 shares during the period. Finally, AQR Capital Management LLC increased its position in Aerovate Therapeutics by 14.7% during the 1st quarter. AQR Capital Management LLC now owns 21,633 shares of the company’s stock worth $54,000 after purchasing an additional 2,779 shares in the last quarter.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. By leveraging a proprietary aerosol delivery platform, the company aims to deliver potent small-molecule anti-fibrotic and anti-inflammatory agents directly to the lungs, thereby maximizing local drug exposure while minimizing systemic side effects.

The company’s lead product candidate is an inhaled formulation of an established anti-fibrotic agent currently in early-phase clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).